Zhuo Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhuo Zhao has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Jinming Zhang
The First Hospital of Jilin University, Jilin University, Changchun 130021, People's Republic of China
3 shared publicationsZiling Yang
The First Hospital of Jilin University, Jilin University, Changchun 130021, People's Republic of China; The Second Hospital of Jilin University, Jilin University, Changchun 130000, People's Republic of China
3 shared publications- Nan Zhang
Department of Gastroenterology, The First Hospital of Jilin University, ChangChun, China
2 shared publications - Chenming Bs Yu
Department of Intervention Radiology, Lishui District People's Hospital, Nanjing, China
1 shared publication - Dandan Zhou
Department of Radiology, The First Hospital of Jilin University, Changchun, China
1 shared publication - Xiangyu Liu
Department of Radiology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China
1 shared publication
Latest Publications
- Open Access
- 24 January 2026
- Published by Elsevier in The Journal of nutrition, health and aging
- Vol. 30 (3) , 100792
Allostatic load elevates the risk and adverse prognosis of immune-mediated inflammatory diseases: modulatory effects of lifestyle interventions and genetic susceptibility
- 24 January 2026
- Published by Elsevier in The Journal of nutrition, health and aging
- Vol. 30 (3) , 100792
Open AccessAllostatic load elevates the risk and adverse prognosis of immune-mediated inflammatory diseases: modulatory effects of lifestyle interventions and genetic susceptibility
- Open Access
- 10 January 2026
- Published by Elsevier in Journal of Affective Disorders
- Vol. 399, 121176
Bidirectional, time-ordered association network linking psychiatric disorders and immune-mediated inflammatory diseases: Inflammation–sleep mediation and genetic modification
- 10 January 2026
- Published by Elsevier in Journal of Affective Disorders
- Vol. 399, 121176
Open AccessBidirectional, time-ordered association network linking psychiatric disorders and immune-mediated inflammatory diseases: Inflammation–sleep mediation and genetic modification
- Open Access
- 17 June 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1367820
Structural and pharmacological insights into cordycepin for neoplasms and metabolic disorders
Cytotoxic adenosine analogues were among the earliest chemotherapeutic agents utilised in cancer treatment. Cordycepin, a natural derivative of adenosine discovered in the fungus Ophiocordyceps sinensis, directly inhibits tumours not only by impeding biosynthesis, inducing apoptosis or autophagy, regulating the cell cycle, and curtailing tumour invasion and metastasis but also modulates the immune response within the tumour microenvironment. Furthermore, extensive research highlights cordycepin’s significant therapeutic potential in alleviating hyperlipidaemia and regulating glucose metabolism. This review comprehensively analyses the structure-activity relationship of cordycepin and its analogues, outlines its pharmacokinetic properties, and strategies to enhance its bioavailability. Delving into the molecular biology, it explores the pharmacological mechanisms of cordycepin in tumour suppression and metabolic disorder treatment, thereby underscoring its immense potential in drug development within these domains and laying the groundwork for innovative treatment strategies.
- 17 June 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1367820
Open AccessStructural and pharmacological insights into cordycepin for neoplasms and metabolic disorders
Cytotoxic adenosine analogues were among the earliest chemotherapeutic agents utilised in cancer treatment. Cordycepin, a natural derivative of adenosine discovered in the fungus Ophiocordyceps sinensis, directly inhibits tumours not only by impeding biosynthesis, inducing apoptosis or autophagy, regulating the cell cycle, and curtailing tumour invasion and metastasis but also modulates the immune response within the tumour microenvironment. Furthermore, extensive research highlights cordycepin’s significant therapeutic potential in alleviating hyperlipidaemia and regulating glucose metabolism. This review comprehensively analyses the structure-activity relationship of cordycepin and its analogues, outlines its pharmacokinetic properties, and strategies to enhance its bioavailability. Delving into the molecular biology, it explores the pharmacological mechanisms of cordycepin in tumour suppression and metabolic disorder treatment, thereby underscoring its immense potential in drug development within these domains and laying the groundwork for innovative treatment strategies.